Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Winner.

Core Insights - The Danish drugmaker's shareholders are relieved that the company has not overpaid for treatments that are largely unproven [1] Company Summary - The company has managed to avoid excessive financial commitments in acquiring treatments that lack substantial evidence of efficacy [1]